IMMUNIC INC (IMUX) Stock Price & Overview
NASDAQ:IMUX • US4525EP1011
Current stock price
The current stock price of IMUX is 1.15 USD. Today IMUX is down by -4.17%. In the past month the price increased by 31.11%.
IMUX Key Statistics
- Market Cap
- 150.029M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.65
- Dividend Yield
- N/A
IMUX Stock Performance
IMUX Stock Chart
IMUX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMUX. When comparing the yearly performance of all stocks, IMUX is one of the better performing stocks in the market, outperforming 92.84% of all stocks.
IMUX Earnings
IMUX Forecast & Estimates
15 analysts have analysed IMUX and the average price target is 4.97 USD. This implies a price increase of 332.39% is expected in the next year compared to the current price of 1.15.
IMUX Groups
Sector & Classification
IMUX Financial Highlights
Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -404.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMUX Ownership
IMUX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 368.381B | ||
| AMGN | AMGEN INC | 15.4 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.98 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.19 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.34 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.76 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.33 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMUX
Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Company Info
IPO: 2014-04-17
IMMUNIC INC
1200 Avenue Of The Americas, Suite 200
New York City NEW YORK 10036 US
CEO: Daniel Vitt
Employees: 92
Phone: 13322559818
IMMUNIC INC / IMUX FAQ
Can you describe the business of IMMUNIC INC?
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Can you provide the latest stock price for IMMUNIC INC?
The current stock price of IMUX is 1.15 USD. The price decreased by -4.17% in the last trading session.
What is the dividend status of IMMUNIC INC?
IMUX does not pay a dividend.
What is the ChartMill rating of IMMUNIC INC stock?
IMUX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for IMUX stock?
15 analysts have analysed IMUX and the average price target is 4.97 USD. This implies a price increase of 332.39% is expected in the next year compared to the current price of 1.15.
Would investing in IMMUNIC INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMUX.
Can you provide the upcoming earnings date for IMMUNIC INC?
IMMUNIC INC (IMUX) will report earnings on 2026-05-13, before the market open.